Tesamorelin / KPV
Also known as: Tesamorelin/KPV, Tesamorelin and KPV blend
Tesamorelin / KPV is a marketing name for a blend of two peptides with different roles. Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog, and KPV is a short anti-inflammatory tripeptide derived from the hormone alpha-MSH. The pairing is marketed to combine a metabolic, growth-hormone effect with an anti-inflammatory one. Tesamorelin is an FDA-approved drug, but only for a specific condition; the combined blend is not an approved product.
What's in this blend
Tesamorelin / KPV combines the following peptides. The blend's effects and risks are those of its components together; open each for its own evidence and safety.
How it works
Tesamorelin mimics GHRH to prompt the pituitary to release the body's own growth hormone, which is documented to reduce visceral fat in its approved population. KPV is studied in laboratory and animal models for calming inflammatory signaling, including in the gut. The tesamorelin-plus-KPV combination has not been studied as a single product in controlled human trials.
Researched uses
- Marketed to combine a growth-hormone and metabolic effect (tesamorelin) with anti-inflammatory support (KPV)
- Tesamorelin is FDA-approved specifically to reduce excess visceral abdominal fat in HIV-associated lipodystrophy
- KPV has been studied for inflammation in laboratory and animal models
Tesamorelin is FDA-approved only to reduce visceral abdominal fat in HIV-associated lipodystrophy; using it in a general blend is off-label, and there is no FDA-approved Tesamorelin/KPV product. KPV is sold as a research chemical and is not an established compounding substance. Providers listed here dispense with a prescription and describe a licensed pharmacy, but because the combination sits outside the settled compounding rules the legal pathway is not clear-cut, so review each provider's own sourcing. Tesamorelin appears on the World Anti-Doping Agency (WADA) Prohibited List; KPV is not specifically listed.
Tesamorelin / KPV providers compared
Providers that have passed our rubric review are listed first, then ordered by the total cost of a 3-month protocol. We average every cost to a standard 3-month protocol, which our medical advisors consider the best basis for comparing cost and value, and the headline figure folds in any one-time consult or provider-review fee plus three months of membership. Use the calculator below to adjust the length and see the same total broken out.
| Provider | Sourcing | What's included | Verified | Visit provider | |
|---|---|---|---|---|---|
Ellie MDVerified Tesamorelin/KPV Injection | 503A pharmacy | $654 for 3 months $218 per month | No consult fee · no membership · shipping included | Jul 7, 2026 | View |
We average every cost to a standard 3-month protocol, which our medical advisors consider the best window for comparing cost and value. Monthly plans are multiplied by 3 and 3-month programs are taken as billed; each provider's own sticker price and cadence are shown underneath.
The headline figure is the total 3-month cost: the medication plus any one-time consult or provider-review fee (for example RxPepsDirect's $39) and three months of any membership fee. Where a fee is not published we fold in what is known and flag that other fees may apply.
Per-vial providers are averaged to a 3-month protocol at roughly one vial per month (3 vials), marked "est.", with the per-vial price shown underneath. Actual vial count depends on your dose and protocol.
Prices are gathered from each provider's public pages. The "Verified" date is when we last checked the provider's sticker price; for per-vial providers it is the vial price that was verified, not the averaged 3-month total.
Value check: total cost of therapy
This is the real value comparison. A sticker price hides consult and membership fees, so this adds everything up for a full protocol of Tesamorelin / KPV and ranks by true total cost. We default to a 3-month protocol, the window our medical advisors consider best for judging value.
Safety notes
The safety of the Tesamorelin / KPV blend has not been established in humans. Tesamorelin can raise IGF-1 and may cause water retention, joint aches, numbness, or changes in blood sugar, and its safety data comes from its approved HIV-lipodystrophy population, which may not transfer to other adults. KPV's evidence is largely preclinical, and the combination is unstudied. Products sold outside the licensed pharmacy system are not verified for identity, purity, or sterility.
In the news
- Inside the booming, gray-market world of injectable peptides The Hill
Reporting on the gray market for research-use-only injectable peptides sold outside the licensed pharmacy system, and the associated health concerns.
Tesamorelin / KPV questions
How much does Tesamorelin / KPV cost?
Across the licensed providers tracked here, a full 3-month protocol of Tesamorelin / KPV totals $654 to $654, depending on the provider, dose, and what is included. We average every cost to a standard 3-month protocol, which our medical advisors consider the best basis for comparing cost and value, and the total folds in any one-time consult or provider-review fee and three months of membership. Each price shows the date the provider's sticker price was verified.
What is Tesamorelin / KPV?
It is a blend of tesamorelin (a growth-hormone-releasing peptide) and KPV (an anti-inflammatory peptide), marketed to combine metabolic and anti-inflammatory effects. Doses vary by provider.
Is it FDA-approved?
Tesamorelin is FDA-approved, but only to reduce visceral fat in HIV-associated lipodystrophy. There is no approved Tesamorelin/KPV product, and using the blend is off-label and unproven.
Is it allowed in sport?
Tesamorelin is on the WADA Prohibited List, so the blend is not appropriate for competitive athletes; KPV is not specifically listed.